page headers Coronavirus

US reviews J&J COVID-19 vaccine


The United States is reviewing reports of a handful of potential cases of severe side effects among people who received Johnson & Johnson's COVID-19 vaccine, as well as those that led to a pause in its use, a top US public health official says.

US health regulators called for a pause in administering the J&J vaccine last week due to reports of serious brain blood clots in six women under age 50 who received the shot out of about seven million vaccinated with it in the United States.

"We are encouraged that it hasn't been an overwhelming number of cases but we're looking and seeing what's come in," US Centers for Disease Control and Prevention (CDC) director Rochelle Walensky said during a Monday news briefing.

The US Food and Drug Administration (FDA) was monitoring the US government's database for additional reports of side effects, she said. Walensky did not provide any details on the nature of the additional side effects.

An advisory panel for the CDC is meeting on Friday to review data on severe side effects and will make a recommendation on whether the United States should resume using the J&J vaccine.

Public health experts have predicted a resumption, but only after healthcare providers are given clear guidelines for how to recognise and treat the blood clots that can emerge as a rare side effect of the vaccine.

J&J's COVID-19 vaccine production ramp up may still move more slowly than originally projected. The FDA has postponed authorisation of a large J&J vaccine plant in the United States because of factory errors that ruined millions of doses last month.

White House COVID-19 adviser Andy Slavitt on Monday assured Americans that vaccine supply remained robust and "it has never been easier" for Americans to obtain a vaccine.

More than three million COVID-19 shots are going into arms each day in the United States using the Pfizer Inc/BioNTech and Moderna Inc two-dose vaccines.

Wealthy governments are looking to COVID-19 shots from Pfizer and Moderna to keep their vaccination programs on track amid mounting concerns about shots from J&J and AstraZeneca.

© RAW 2021